Previous 10 | Next 10 |
Montrouge, France, November 5, 2019 DBV Technologies to Present at the Stifel 2019 Healthcare Conference DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Kevin Trapp, Chief Commercial Off...
Montrouge, France, October 24, 2019 DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 New analysis evaluates quality of life in patients receiving investigational Viaskin Peanut DBV Technologies (Euronext: DBV - ISIN:...
Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) DBV Technologies (the “Company ...
DBV Technologies (NASDAQ: DBVT ) has priced its global offering of (i) 7,914,622 ordinary shares (15,829,244 ADSs) in U.S., Canada and countries outside Europe at $6.59/ADS (ii) a private placement of 1,569,444 ordinary shares in Europe (including France) at €12.04/ordinary share. ...
DBV Technologies Announces Pricing of $125 million ( € 114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: D...
Montrouge, France, October 8, 2019 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position DBV Technologies (the “Company”) (Euronext: DBV &...
Gainers: Asure Software (NASDAQ: ASUR ) +22% . SunLink Health Systems (NYSEMKT: SSY ) +10% . AgeX Therapeutics (NYSEMKT: AGE ) +9% . NIO (NYSE: NIO ) +9% . ATIF Holdings (NASDAQ: ATIF ) +8% . Frontier Communications Corporation (NASDAQ: FTR ) +8% . Nordic American Tankers Limit...
According to industry and sector data analysed by GlobalData, Merck's ( MRK ) Keytruda will reportedly become the world's top-selling drug by 2025, with estimated sales of over $22 billion. Wall Street consensus estimate pegs nearly $20 billion annual sales for Keytruda by 2023. Bristol-Myer...
QIAGEN (NYSE: QGEN ) -18% on reporting preliminary Q3 results. More news on: QIAGEN N.V., Ocugen, Inc., Ambarella, Inc., Stocks on the move, Read more ...
DBV Technologies ( DBVT +2.8% ) says the Food and Drug Administration has accepted the Biologics License Application for its Viaskin peanut immunotherapy for the treatment of peanut-allergic children aged 4-11; shares are halted. More news on: DBV Technologies S.A., Healthcare stocks n...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...